NCT02929797

Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer

A Randomized, Double Blinding, Placebo-Controlled Clinical Trials of CD8+NKG2D+ AKT Cell Immunotherapy to the Pancreatic Cancer Patients Treated With Adjuvant Chemotherapy

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.

Conditions

• Pancreatic Ductal Adenocarcinoma

Interventions

Type	Name	Description
BIOLOGICAL	CD8+NKG2D+ AKT Cell	AKT: CD8+NKG2D+ AKT cell
DRUG	Gemcitabine	gemcitabine

Timeline

• Start date: 2016-08-01
• Primary completion: 2017-08-01
• Completion: 2019-08-01
• First posted: 2016-10-11
• Last updated: 2016-10-11

Locations

2 sites across 1 country: China